PolyPid (PYPD) Q2 2026 earnings summary

Executive summary

• FDA accepted NDA for D-PLEX100 with priority review, no filing review issues, and set a PDUFA goal date of November 28, 2026, ahead of prior guidance.

• Entered exclusive commercialization partnership with Azurity Pharmaceuticals for U.S. and Canada, securing $30M in upfront and near-term milestone payments, with potential for over $290M in additional milestones and tiered royalties.

• Manufacturing readiness validated by four consecutive successful GMP inspections and external due diligence by partners.

• Planned MAA submission to the European Medicines Agency in Q3 2026, targeting EU-wide approval.

• Kynatrix technology pipeline progressing, including long-acting metabolic and infection programs.

Financial highlights

• Secured $30M in upfront and near-term milestone payments from Azurity partnership.

• Eligible for over $290M in additional regulatory, launch, and sales milestones.

• Q2 2026 R&D expenses were $6.1M (vs. $6.2M in Q2 2025); G&A expenses $1.3M (vs. $2.5M); marketing/business development $0.5M (vs. $0.7M).

• Q2 2026 net loss was $7.8M ($0.35/share), improved from $10M ($0.78/share) in Q2 2025.

• Cash and equivalents at June 30, 2026: $6.6M, strengthened post-quarter by $30M from Azurity.

Outlook and guidance

• Expect commercial launch of D-PLEX100 in U.S. in early 2027.

• Existing cash and expected proceeds sufficient to fund operations into 2028 and through key milestones.

• No immediate financing needs anticipated.

• MAA submission to EMA for D-PLEX100 expected in Q3 2026.